New Wegovy pill, same drug: has anything changed?
16 July 2026The launch of GLP-1 drugs in tablet form does not change their purpose, but it could change who reaches for them and how they’re used.
The new format increases new user uptake
Oral semaglutide (the Wegovy pill) was approved by the MHRA on 11 June 2026 and launched in the UK on 6 July, available initially through private prescription. It is licensed on the same clinical basis as the injection: adults with a BMI of 30 or above, or 27–30 with a weight-related condition.
Jamie Kerruish, Chief Healthcare Officer at Boots UK, said: “We’ve seen unprecedented interest since the launch of the oral Wegovy tablet; launch day was one of our biggest ever days for customer consultations.”
Needle aversion is a significant barrier to care affecting at least 1 in 10 people, it keeps some people out of treatment altogether and pushes others toward less effective or unregulated alternatives. The tablet removes this barrier for a subset of people who need support and have been avoiding it. The same removal of friction that helps someone with a real clinical need to obtain support could also draw in more people seeking a quick fix rather than sustained behaviour change.
The key question is whether oral medicines mainly shift existing users from injections or expand the treated population. In the US, where Wegovy pills went on sale at the start of January, data shows a mixed pattern. Truveta’s early analysis found 36% of users were new to GLP-1 medication. Among new users, more are men, who make up a smaller proportion of the current GLP-1 weight-loss community.
Adherence still matters
Adherence could also affect efficacy. Oral semaglutide must be taken on an empty stomach after fasting, with a sip of up to 120ml of plain water, with no food or drink for at least 30 minutes afterwards to allow for effective absorption of the drug. For some users, this may be preferable to injections; for others, daily dosing may be less convenient than a weekly injection. The experience of use, including side effects, will affect persistence and the extent of any consumption-related behaviour change.
This matters clinically because the efficacy data assumes adherence. In the OASIS 4 trial, participants taking the tablet an average of 14% of body weight over 64 weeks, which broadly comparable to injections, with some studies showing the injections result in slightly more weight loss. The OASIS 4 trial population was provided with structured support and monitoring. Real-world adherence to a fasting-dependent daily tablet, outside a trial setting, may show different effects.
Access is widening, but not equally
The tablet could alter access routes, but it does not remove market constraints. In the UK, access is likely to remain shaped by private prescription in the near term, while NHS availability depends on further evaluation and implementation that is unlikely to conclude in 2026.
Marketing remains restricted for this prescription medication; within these confines, providers have been highlighting the availability of new options and starting prices.
While starting doses are available at comparatively lower prices than injectable Wegovy, they may not reflect the longer-term cost of treatment as doses increase.
Treatment stage | Injection | Pill | Pill vs injection % |
Starter | £79.97 | £99.00 (£79.99 new customer discount) | +23.8% |
Escalation dose 1 | £114.97 | £119.00 | +3.5% |
Escalation dose 2 | £166.97 | £149.00 | -10.8% |
Escalation dose 3 | £192.97 | n/a | n/a |
Maintenance | £205.97 | £229.00 | +11.2% |
Higher maintenance | £285.97 | n/a | n/a |
Source: Boots.com, July 2026
In practical terms, the tablet expands access for people who can pay for it. This has less of an impact on the wider population who might benefit most and who are more likely to be relying on NHS weight management services.
GLP-1 tablets change could challenge existing assumptions
A tablet will not make GLP-1s mass-market overnight. It also doesn’t change the underlying reality that sustained weight management requires continued use of a GLP-1 drug or depends on the food environment people return to every day. But in a market where format, access and consumer confidence can affect adoption, it’s a significant development.
Manufacturers need to understand how oral treatments could change the scale and behaviour of the GLP-1 user base. IGD Futures GLP-1 research programme will continue tracking how medication use is reshaping consumer needs, category demand and commercial opportunities for retailers and suppliers — get in touch to learn more: [email protected].